@article{WernerHiguchiPomperetal.2021, author = {Werner, Rudolf A. and Higuchi, Takahiro and Pomper, Martin G. and Rowe, Steven P.}, title = {Theranostics in oncology — thriving, now more than ever}, series = {Diagnostics}, volume = {11}, journal = {Diagnostics}, number = {5}, issn = {2075-4418}, doi = {10.3390/diagnostics11050805}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-236662}, year = {2021}, abstract = {Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful mainly due to the beneficial effects of image-guided therapeutic concepts for patients afflicted with a variety of different cancers. The majority of these treatments are not only characterized by substantial prolongation of progression-free and overall survival, but are also generally safe, rendering theranostic agents as an attractive treatment option in various clinical scenarios in oncology. In this Special Issue Novel Theranostic Agents, nine original articles from around the globe provide further evidence on the use of the theranostic concept for neuroendocrine neoplasm (NEN), prostate cancer (PC), meningioma, and neuroblastoma. The investigated diagnostic and therapeutic radiotracers target not only established structures, such as somatostatin receptor, prostate-specific membrane antigen or norepinephrine transporter, but also recently emerging targets such as the C-X-C motif chemokine receptor 4. Moreover, the presented original articles also combine the concept of theranostics with in-depth read-out techniques such as radiomics or novel reconstruction algorithms on pretherapeutic scans, e.g., for outcome prediction. Even 80 years after its initial clinical introduction, theranostics in oncology continues to thrive, now more than ever.}, language = {en} } @article{LisowskiHartrampfHasenaueretal.2023, author = {Lisowski, Dominik and Hartrampf, Philipp E. and Hasenauer, Natalie and Nickl, Vera and Monoranu, Camelia-Maria and Tamihardja, J{\"o}rg}, title = {Complete loss of E-cadherin expression in a rare case of metastatic malignant meningioma: a case report}, series = {BMC Neurology}, volume = {23}, journal = {BMC Neurology}, doi = {10.1186/s12883-023-03450-w}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-357996}, year = {2023}, abstract = {Background Hematogenous tumor spread of malignant meningiomas occurs very rarely but is associated with very poor prognosis. Case presentation We report an unusual case of a patient with a malignant meningioma who developed multiple metastases in bones, lungs and liver after initial complete resection of the primary tumor. After partial hepatic resection, specimens were histologically analyzed, and a complete loss of E-cadherin adhesion molecules was found. No oncogenic target mutations were found. The patient received a combination of conventional radiotherapy and peptide receptor radionuclide therapy (PRRT). Due to aggressive tumor behavior and rapid spread of metastases, the patient deceased after initiation of treatment. Conclusions E-cadherin downregulation is associated with a higher probability of tumor invasion and distant metastasis formation in malignant meningioma. Up to now, the efficacy of systemic therapy, including PRRT, is very limited in malignant meningioma patients.}, language = {en} } @article{LillaKesslerWeilandetal.2021, author = {Lilla, Nadine and Kessler, Almuth F. and Weiland, Judith and Ernestus, Ralf-Ingo and Westermaier, Thomas}, title = {Case Report: A Case Series Using Natural Anatomical Gaps — Posterior Cervical Approach to Skull Base and Upper Craniocervical Meningiomas Without Bone Removal}, series = {Frontiers in Surgery}, volume = {8}, journal = {Frontiers in Surgery}, issn = {2296-875X}, doi = {10.3389/fsurg.2021.666699}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-244613}, year = {2021}, abstract = {Background: Removal of anteriorly located tumors of the upper cervical spine and craniovertebral junction (CVJ) is a particular surgical challenge. Extensive approaches are associated with pain, restricted mobility of neck and head and, in case of foramen magnum and clivus tumors, with retraction of brainstem and cerebellum. Methods: Four symptomatic patients underwent resection of anteriorly located upper cervical and lower clivus meningiomas without laminotomy or craniotomy using a minimally invasive posterior approach. Distances of natural gaps between C0/C1, C1/C2, and C2/C3 were measured using preoperative CT scans and intraoperative lateral x-rays. Results: In all patients, safe and complete resection was conducted by the opening of the dura between C0/C1, C1/C2, and C2/C3, respectively. There were no surgical complications. Local pain was reported as very moderate by all patients and postoperative recovery was extremely fast. All tumors had a rather soft consistency, allowing mass reduction prior to removal of the tumor capsule and were well separable from lower cranial nerves and vascular structures. Conclusion: If tumor consistency is appropriate for careful mass reduction before removal of the tumor capsule and if tumor margins are not firmly attached to crucial structures, then upper cervical, foramen magnum, and lower clivus meningiomas can be safely and completely removed through natural gaps in the CVJ region. Both prerequisites usually become clear early during surgery. Thus, this tumor entity may be planned using this minimally invasive approach and may be extended if tumor consistency turns out to be less unfavorable for resection or if crucial structures cannot be easily separated from the tumor.}, language = {en} } @article{JungwirthYuMoustafaetal.2019, author = {Jungwirth, Gerhard and Yu, Tao and Moustafa, Mahmoud and Rapp, Carmen and Warta, Rolf and Jungk, Christine and Sahm, Felix and Dettling, Steffen and Zweckberger, Klaus and Lamszus, Katrin and Senft, Christian and Loehr, Mario and Keßler, Almuth F. and Ketter, Ralf and Westphal, Manfred and Debus, Juergen and von Deimling, Andreas and Simon, Matthias and Unterberg, Andreas and Abdollahi, Amir and Herold-Mende, Christel}, title = {Identification of KIF11 as a Novel Target in Meningioma}, series = {Cancers}, volume = {11}, journal = {Cancers}, number = {4}, issn = {2072-6694}, doi = {10.3390/cancers11040545}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-197402}, year = {2019}, abstract = {Kinesins play an important role in many physiological functions including intracellular vesicle transport and mitosis. The emerging role of kinesins in different cancers led us to investigate the expression and functional role of kinesins in meningioma. Therefore, we re-analyzed our previous microarray dataset of benign, atypical, and anaplastic meningiomas (n = 62) and got evidence for differential expression of five kinesins (KIFC1, KIF4A, KIF11, KIF14 and KIF20A). Further validation in an extended study sample (n = 208) revealed a significant upregulation of these genes in WHO°I to °III meningiomas (WHO°I n = 61, WHO°II n = 88, and WHO°III n = 59), which was most pronounced in clinically more aggressive tumors of the same WHO grade. Immunohistochemical staining confirmed a WHO grade-associated upregulated protein expression in meningioma tissues. Furthermore, high mRNA expression levels of KIFC1, KIF11, KIF14 and KIF20A were associated with shorter progression-free survival. On a functional level, knockdown of kinesins in Ben-Men-1 cells and in the newly established anaplastic meningioma cell line NCH93 resulted in a significantly inhibited tumor cell proliferation upon siRNA-mediated downregulation of KIF11 in both cell lines by up to 95\% and 71\%, respectively. Taken together, in this study we were able to identify the prognostic and functional role of several kinesin family members of which KIF11 exhibits the most promising properties as a novel prognostic marker and therapeutic target, which may offer new treatment options for aggressive meningiomas.}, language = {en} }